Abstract: According to one aspect of the disclosure, packaging for a sterile syringe having a nominal size of less than 1 mL may include a flexible tray having a cavity for containing the syringe. The cavity may include an opening, one or more sidewalls, and a base. A lip may surround the opening, may extend radially outward from the cavity, and may define a periphery of the tray. A removable cover may have a periphery that is adhered to the lip, and the removable cover may be permeable to a gaseous sterilant, including one or more of vaporized hydrogen peroxide or ethylene oxide. A projection may be associated with the base of the cavity and may extend away from the base of the cavity in a direction opposite to the opening of the cavity.
Abstract: Compositions and methods are provided for creating and promoting biallelic targeted modifications to genomes within cells and for producing non-human animals comprising the modified genomes. Also provided are compositions and methods for modifying a genome within a cell that is heterozygous for an allele to become homozygous for that allele. The methods make use of Cas proteins and two or more guide RNAs that target different locations within the same genomic target locus. Also provided are methods of identifying cells with modified genomes.
Type:
Application
Filed:
May 15, 2023
Publication date:
October 19, 2023
Applicant:
Regeneron Pharmaceuticals, Inc.
Inventors:
David Frendewey, Ka-Man Venus Lai, Wojtek Auerbach, Gustavo Droguett, Anthony Gagliardi, David M. Valenzuela, Vera Voronina, Lynn Macdonald, Andrew J. Murphy, George D. Yancopoulos
Abstract: The present invention provides antibody-tethered drug conjugates (ATDCs) and compositions thereof that are useful, for example, for targeting glucagon-like peptide 1 receptor (GLP1R) and treating various conditions, e.g., diabetes. Methods for making such ATDCs are also provided along with method of use thereof.
Type:
Application
Filed:
March 11, 2023
Publication date:
October 19, 2023
Applicant:
Regeneron Pharmaceuticals, Inc.
Inventors:
Haruka OKAMOTO, Jean YANOLATOS, AMY HAN, Xiang ZHENG, William OLSON, Andrew J. MURPHY, Frank DELFINO
Abstract: Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR), compositions comprising the antibodies or antigen-binding fragments thereof, and methods of using the same, including, e.g., methods of treatment using the same.
Type:
Grant
Filed:
March 5, 2021
Date of Patent:
October 17, 2023
Assignee:
REGENERON PHARMACEUTICALS, INC.
Inventors:
Robert Babb, Drew Dudgeon, Yu Huang, Rosalynn Molden, William Olson, Matthew Sleeman, Dimitris Skokos, Bei Wang
Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
Type:
Grant
Filed:
September 19, 2019
Date of Patent:
October 17, 2023
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
Abstract: A method for site-specific quantitation or characterization of drug conjugations of antibody-drug conjugates using protease-assisted drug deconjugation, linker labelling and mass spectrometry, wherein the conjugation includes an attachment linked to a specific conjugation site of a partially conjugated peptide or protein in a sample. The method comprises cleaving a portion of the attachment to generate the peptide or protein containing a cleaved linker, adding a modified linker to an unconjugated conjugation site of the partially conjugated peptide or protein, and subsequently subjecting the sample to mass analysis to identify the peptide or protein containing the cleaved linker and/or the modified linker.
Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antibodies including bispecific antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing an expression-enhancing locus.
Type:
Application
Filed:
November 10, 2022
Publication date:
October 12, 2023
Applicant:
Regeneron Pharmaceuticals, Inc.
Inventors:
Robert BABB, Darya BURAKOV, Gang CHEN, James P. FANDL
Abstract: The present disclosure provides antibodies and antigen-binding fragments of antibodies that bind to Pseudomonas aeruginosa PcrV, and methods of using the same. According to certain embodiments, the disclosure includes antibodies and antigen-binding fragments of antibodies that bind PcrV. The anti-PcrV antibodies and antigen-binding fragments are useful for the prevention and treatment of P. aeruginosa infections.
Abstract: Cas-protein-ready tau bio sensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic vulnerability associated with tau aggregation are provided.
Type:
Grant
Filed:
March 17, 2020
Date of Patent:
October 10, 2023
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Marine Prissette, Matthew Koss, Yu Bai, Brian Zambrowicz
Abstract: Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods.
Type:
Grant
Filed:
August 21, 2020
Date of Patent:
October 10, 2023
Assignees:
Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine (IRB)
Inventors:
Richard Flavell, Till Strowig, Markus G. Manz, Chiara Borsotti, Madhav Dhodapkar, Andrew J. Murphy, Sean Stevens, George D. Yancopoulos
Abstract: The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing influenza virus activity, thus providing a means of treating or preventing influenza infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the influenza HA for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.
Type:
Grant
Filed:
January 24, 2019
Date of Patent:
October 10, 2023
Assignee:
REGENERON PHARMACEUTICALS, INC.
Inventors:
Lisa A. Purcell, Jonathan Viau, William Olson
Abstract: The present invention provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion proteins are GLP1 receptor agonists that comprise a modified GLP1 fused to a stabilizing domain. In some embodiments, the fusion proteins comprising modified GLP1 are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.
Type:
Grant
Filed:
May 27, 2021
Date of Patent:
October 10, 2023
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Yang Wei, Haruka Okamoto, Jesper Gromada, Samuel Davis, Andrew J. Murphy
Abstract: Methods for detecting and/or discriminating between variants of an antibody contaminating protein or multiple antibodies in a sample by a physical parameter, in which the method includes: separating protein components of a sample by molecular weight or charge in one or more capillaries using capillary electrophoresis; immobilizing the protein components of the sample within the one or more capillaries; contacting the protein components within the one or more capillaries with one or more primary antibodies that specifically bind to the antibody, the contaminating protein or multiple antibodies in the sample, thereby detecting and/or discriminating between variants in the sample.
Type:
Grant
Filed:
December 17, 2019
Date of Patent:
October 10, 2023
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Nisha Palackal, Kun Lu, Gangadhar Dhulipala, Erica Pyles
Abstract: Provided herein are monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza B hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies are useful for inhibiting or neutralizing influenza B virus activity, thus providing a means of treating or preventing influenza infection in humans. Also provided is the use of one or more antibodies that bind to the influenza B HA for preventing viral attachment and/or entry into host cells. The antibodies may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.
Abstract: The present invention provides methods for preventing or treating allergy. Also provided are methods for reducing the susceptibility to an allergen in a subject in need thereof. In certain embodiments, the subject has a disease or disorder selected from the group consisting of atopic dermatitis, asthma, allergic rhinitis, and eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.
Abstract: The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.
Type:
Grant
Filed:
April 14, 2020
Date of Patent:
October 3, 2023
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Christopher Daly, Douglas MacDonald, Xunbao Duan
Abstract: The present disclosure provides methods of treating subjects having a liver disease, and methods of identifying subjects having an increased risk of developing liver disease.
Type:
Grant
Filed:
March 31, 2022
Date of Patent:
October 3, 2023
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Niek Verweij, Luca Andrea Lotta, Aris Baras, Mary Haas, Jonas Nielsen, Olukayode Sosina, Adam Locke
Abstract: The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.
Type:
Grant
Filed:
January 21, 2020
Date of Patent:
September 26, 2023
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Kavita Praveen, Claudia Schurmann, Lauren Gurski, Tanya Teslovich Dostal, Goncalo Abecasis, Aris Baras, Giovanni Coppola, Carmelo Romano